Proud to have our President, Research and Development, Dominic Borie, M.D., Ph.D. presenting at the 13th?HUHRD (Hanyang University Hospital for Rheumatic Diseases) International Symposium to advance the knowledge around?#cartcelltherapy?in the treatment of?#autoimmunedisease. For more information: https://lnkd.in/gvhsdvum #KYV101 #AskKyverna??
Kyverna Therapeutics
生物技术研究
Emeryville，California 15,089 位关注者
Harnessing the power of cell therapy in autoimmune disease.
关于我们
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
- 网站
-
https://kyvernatx.com
Kyverna Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Emeryville，California
- 类型
- 上市公司
- 创立
- 2018
- 领域
- cell therapy、autoimmune、lupus、multiple sclerosis、systemic sclerosis、scleroderma、myasthenia gravis、CAR T-cell和stiff-person syndrome
地点
-
主要
获取路线
5980 Horton St
Suite 550
US，California，Emeryville，94608
Kyverna Therapeutics员工
动态
-
Proud to have been the 'Featured Presenter' at the Cell Therapy Manufacturing session during the 16th Annual Bioprocessing Summit in Boston last week. The event brought together leaders from industry and academia, where our clinical product data saw significant interest. #CARTCellTherapy #KYV101
-
-
Thank you Shamekka Marty PMP, CSM for being a voice for the voiceless and a fierce advocate for patient and caregiver education about potential shifts in the treatment paradigm for #autoimmunedisease. It was a pleasure hosting you at the Village.
2023 Sequioa Project Patient Volunteer of the Year| Cybersecurity Consultant | Healthcare Interoperability | Patient Advocate | Speaker | Connector | IT Project Manager | Certified Scrum Master
Thank you, Kyverna Therapeutics, for the opportunity to speak with you today about my experiences living with #lupus. It's vital that we work together to reach more individuals and change the stigma surrounding clinical trials for #CAR T-cell therapy, as well as the importance of patient informed consent in regards to wearable devices. I truly appreciate the leadership within your company for engaging with #patient advocates; it shows a commitment to understanding our community's needs. I'm excited to see how dedicated your team is to improving treatments for lupus and exploring the possibility of a cure. I look forward to learning more about the studies on CAR T-cell therapy and its impact on #autoimmune diseases. #cartcelltherapy #lupus #autoimmunedisease #ms #scleraderma #patientadvocate #informedconsent
-
-
Pleased to share we have received our second U.S. FDA RMAT Designation for #KYV101 in the treatment of patients with progressive myasthenia gravis. The application was evaluated based on the positive clinical outcomes in patients treated in Germany under the named-patient program. The Regenerative Medicine Advanced Therapies designation allows Kyverna to leverage more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV-101. #myastheniagravis #cartcelltherapy https://lnkd.in/g7J3AQ5x
-
-
Prof Dimitrios Mougiakakos recently visited the Kyverna village. It was encouraging to hear him say:" I am impressed by the work and cooperative spirit of the Kyverna team. It's great to see the current clinical experience building, in particular the emerging safety data. We have not seen severe CRS and ICANs in patients with autoimmune disease treated with KYV-101."
-
-
Carrie Robinette has #StiffPersonSyndrome, though getting a diagnosis wasn’t quick. Few doctors have seen Stiff-Person Syndrome, let alone know how to treat it. Kyverna’s business unit head of rare diseases, Sham Dholakia, recently spoke with Carrie for Business Insider about the challenges doctors face in diagnosing SPS. https://lnkd.in/giXaW9QB
-
-
Today is National Intern Day! At Kyverna Therapeutics, we are thrilled to celebrate our four amazing 2024 summer interns. Throughout their internship, each of them has shown exceptional talent and an incredible commitment to learning. To our interns, thank you for your dedication and passion to our mission of harnessing the power of CAR-T Cell Therapy for autoimmune diseases. We look forward to your future achievements and are proud to have been part of your professional development. Tatum Laird Kieran V. Max McLeod Xinyang Chen #NationalInternDay
-
-
Stiff-Person Syndrome has gained greater attention after popular singer?Celine Dion announced her diagnosis in 2022. This disease causes muscles?to lock up and become stiff, leading to painful spasms. Our Business Head of Rare Disease, Dr. Sham Dholakia, shares with?PharmaVoice’s Amy Baxter the vision of our CAR-T cell therapy in?targeting SPS, the impact of Dion’s public diagnosis, and the future of CAR-T in the autoimmune space. #CARtcelltherapy #autoimmunedisease #stiffpersonsyndrome #HopeforSPS https://lnkd.in/eSuBdd56?
-
Following the FDA granting Kyverna a Regenerative Medicine Advanced Therapy designation for patients with refractory Stiff-Person Syndrome, our CEO Peter Maag shares with Healio that data generated from our clinical trials will improve our understanding of how KYV-101 can represent a paradigm shift in patients' treatment. #CARTcelltherapy #stiffpersonsyndrome #KYV101 https://lnkd.in/ekZHYgqi
FDA grants RMAT designation for stiff person syndrome therapy
healio.com
-
With the Regenerative Medicine Advanced Therapies (RMAT) designation for KYV-101 in patients with refractory Stiff-Person Syndrome, Kyverna will be able to receive expert guidance from senior FDA officials on efficient drug development and use of surrogate endpoints. Our CEO Peter Maag discusses the significance of the RMAT designation, Kyverna's commitment to patient-centric trials, and the potential of KYV-101 to improve the lives of patients with autoimmune diseases with Fox News Media’s Melissa Rudy. Amanda Piquet, MD, FAAN also shares her optimism about the potential treatment advancements and patient outcomes in SPS. #CARTcelltherapy #stiffpersonsyndrome #KYV101 https://lnkd.in/ebz6YJ9M
New drug for stiff person syndrome granted designation to speed up development: ‘Thrilled for the community’
foxnews.com